肝细胞癌治疗后的影像学评价标准及应用

王文军; 赵艳; 韩国宏

doi:10.3969/j.issn.1001-5256.2016.01.009

肝细胞癌治疗后的影像学评价标准及应用

DOI: 10.3969/j.issn.1001-5256.2016.01.009

第四军医大学西京消化病医院消化介入科

详细信息

中图分类号: R735.7
计量
- 文章访问数: 3059
- HTML全文浏览量: 37
- PDF下载量: 596
- 被引次数: 0
出版历程
- 收稿日期: 2015-12-02
- 出版日期: 2016-01-20

Radiological evaluation after treatment of hepatocellular carcinoma: criteria and application

Department of Liver Disease and Digestive Interventional Radiology,Xijing Hospital of Digestive Disease,Fourth Military Medical University

摘要

摘要: 早期准确的疗效评价有助于临床医师决定是否继续或者改变现有治疗方案。简述了肿瘤疗效评价标准的发展过程;阐述了影像学评价标准在经局部介入或索拉非尼治疗肝细胞癌(HCC)中的应用,并对目前临床主要应用的4种影像学评价标准,即世界卫生组织(WTO)标准、实体瘤疗效评价标准(RECIST)、欧洲肝病学会(EASL)标准和mRECIST(modified RECIST)标准进行了比较,认为EASL和mRECIST标准优于WHO和RECIST标准,可以在早期时间点上预测HCC患者的预后情况。
- 癌,肝细胞 /
- 疗效评价 /
- 诊断显像
Abstract: An early and accurate response evaluation is essential for clinicians to decide whether to continue the treatment with current therapeutic regimen or to make necessary changes. This article briefly introduces the development of response evaluation criteria for tumors,elaborates on the application of radiological evaluation criteria in local interventional therapy or sorafenib treatment of hepatocellular carcinoma( HCC),compares the four radiological evaluation criteria,i. e.,World Health Organization( WHO) criteria,Response Evaluation Criteria in Solid Tumors( RECIST),European Association for the Study of Liver( EASL) criteria,and the modified RECIST( mRECIST),and thinks that EASL criteria and mRECIST are better than WHO criteria and RECIST and can predict the prognosis of HCC patients at earlier time points.
- carcinoma,hepatocellular /
- response evaluation /
- diagnostic imaging

HTML全文

参考文献(40)

[1]TORRE LA,BRAY F,SIEGEL RL,et al.Global cancer statistics,2012[J].CA Cancer J Clin,2015,65(2):87-108.

[2] BRUIX J,SHERMAN M,American Association for the Study of Liver Diseases.Management of hepatocellular carcinoma:an update[J].Hepatology,2011,53(3):1020-1022.

[3]European Association for the Study of the Liver,European Organisation for Research and Treatment of Cancer.EASL-EORTC clinical practice guidelines:management of hepatocellular carcinoma[J].J Hepatol,2012,56(4):908-943.

[4]LLOVET JM,DI BISCEGLIE AM,BRUIX J,et al.Design and endpoints of clinical trials in hepatocellular carcinoma[J].J Natl Cancer Inst,2008,100(10):698-711.

[5]MILLER AB,HOOGSTRATEN B,STAQUET M,et al.Reporting results of cancer treatment[J].Cancer,1981,47(1):207-214.

[6]THERASSE P,ARBUCK SG,EISENHAUER EA,et al.New guidelines to evaluate the response to treatment in solid tumors.European organization for research and treatment of cancer,national cancer institute of the United States,national cancer institute of Canada[J].J Natl Cancer Inst,2000,92(3):205-216.

[7]EISENHAUER EA,THERASSE P,BOGAERTS J,et al.New response evaluation criteria in solid tumours:revised RECIST guideline(version 1.1)[J].Eur J Cancer,2009,45(2):228-247.

[8]BRUIX J,SHERMAN M,LLOVET JM,et al.Clinical management of hepatocellular carcinoma.Conclusions of the Barcelona-2000 EASL conference.European Association for the Study of the Liver[J].J Hepatol,2001,35(3):421-430.

[9]LENCIONI R,LLOVET JM.Modified RECIST(mRECIST)assessment for hepatocellular carcinoma[J].Semin Liver Dis,2010,30(1):52-60.

[10]SATO K,LEWANDOWSKI RJ,BUI JT,et al.Treatment of unresectable primary and metastatic liver cancer with yttrium-90 microspheres(TheraS phere):assessment of hepatic arterial embolization[J].Cardiovasc Intervent Radiol,2006,29(4):522-529.

[11]FORNER A,AYUSO C,VARELA M,et al.Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma:are response evaluation criteria in solid tumors reliable?[J].Cancer,2009,115(3):616-623.

[12]RIAZ A,MILLER FH,KULIK LM,et al.Imaging response in the primary index lesion and clinical outcomes following transarterial locoregional therapy for hepatocellular carcinoma[J].JAMA,2010,303(11):1062-1069.

[13]MEMON K,KULIK L,LEWANDOWSKI RJ,et al.Radiographic response to locoregional therapy in hepatocellular carcinoma predicts patient survival times[J].Gastroenterology,2011,141(2):526-535.

[14]GILLMORE R,STUART S,KIRKWOOD A,et al.EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization[J].J Hepatol,2011,55(6):1309-1316.

[15]SHIM JH,LEE HC,KIM SO,et al.Which response criteria best help predict survival of patients with hepatocellular carcinoma following chemoembolization?A validation study of old and new models[J].Radiology,2012,262(2):708-718.

[16]JUNG ES,KIM JH,YOON EL,et al.Comparison of the methods for tumor response assessment in patients with hepatocellular carcinoma undergoing transarterial chemoembolization[J].J Hepatol,2013,58(6):1181-1187.

[17]EDELINE J,BOUCHER E,ROLLAND Y,et al.Comparison of tumor response by response evaluation criteria in solid tumors(RECIST)and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma[J].Cancer,2012,118(1):147-156.

[18]RONOT M,BOUATTOUR M,WASSERMANN J,et al.Alternative response criteria(Choi,European association for the study of the liver,and modified response evaluation criteria in solid tumors[RECIST])versus RECIST 1.1 in patients with advanced hepatocellular carcinoma treated with sorafenib[J].Oncologist,2014,19(4):394-402.

[19]TAKADA J,HIDAKA H,NAKAZAWA T,et al.Modified response evaluation criteria in solid tumors is superior to response evaluation criteria in solid tumors for assessment of responses to sorafenib in patients with advanced hepatocellular carcinoma[J].BMC Res Notes,2015,8:609.

[20]KIM BK,KIM KA,PARK JY,et al.Prospective comparison of prognostic values of modified response evaluation criteria in solid tumours with European Association for the study of the liver criteria in hepatocellular carcinoma following chemoembolisation[J].Eur J Cancer,2013,49(4):826-834.

[21]SHIM JH,LEE HC,WON HJ,et al.Maximum number of target lesions required to measure responses to transarterial chemoembolization using the enhancement criteria in patients with intrahepatic hepatocellular carcinoma[J].J Hepatol,2012,56(2):406-411.

[22]KIM BK,KIM SU,KIM MJ,et al.Number of target lesions for EASL and modified RECIST to predict survivals in hepatocellular carcinoma treated with chemoembolization[J].Clin Cancer Res,2013,19(6):1503-1511.

[23]KIM BK,KIM SU,KIM KA,et al.Complete response at first chemoembolization is still the most robust predictor for favorable outcome in hepatocellular carcinoma[J].J Hepatol,2015,62(6):1304-1310.

[24]KIM CJ,KIM HJ,PARK JH,et al.Radiologic response to transcatheter hepatic arterial chemoembolization and clinical outcomes in patients with hepatocellular carcinoma[J].Liver Int,2014,34(2):305-312.

[25]TACHER V,LIN M,DURAN R,et al.Comparison of existing response criteria in patients with hepatocellular carcinoma treated with transarterial chemoembolization using a 3D quantitative approach[J].Radiology,2016,278(1):275-284.

[26]LIU L,WANG W,CHEN H,et al.EASL-and mRECIST-evaluated responses to combination therapy of sorafenib with transarterial chemoembolization predict survival in patients with hepatocellular carcinoma[J].Clin Cancer Res,2014,20(6):1623-1631.

[27]GEORGIADES C,GESCHWIND JF,HARRISON N,et al.Lack of response after initial chemoembolization for hepatocellular carcinoma:does it predict failure of subsequent treatment?[J].Radiology,2012,265(1):115-123.

[28]WANG W,ZHAO Y,BAI W,et al.Response assessment for HCC patients treated with repeated TACE:the optimal time-point is still an open issue[J].J Hepatol,2015,63(6):1530-1531.

[29]CHOI H,CHARNSANGAVEJ C,FARIA SC,et al.Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate:proposal of new computed tomography response criteria[J].J Clin Oncol,2007,25(13):1753-1759.

[30]DUDECK O,ZEILE M,REICHARDT P,et al.Comparison of RECIST and Choi criteria for computed tomographic response evaluation in patients with advanced gastrointestinal stromal tumor treated with sunitinib[J].Ann Oncol,2011,22(8):1828-1833.

[31]KUDO M,UESHIMA K,KUBO S,et al.Response evaluation criteria in cancer of the liver(RECICL)(2015 revised version)[J].Hepatol Res,2015.[Epub ahead of print]

[32]LIN M,PELLERIN O,BHAGAT N,et al.Quantitative and volumetric European Association for the Study of the Liver and Response Evaluation Criteria in Solid Tumors measurements:feasibility of a semiautomated software method to assess tumor response after transcatheter arterial chemoembolization[J].J Vasc Interv Radiol,2012,23(12):1629-1637.

[33]CHEN G,MA DQ,HE W,et al.Computed tomography perfusion in evaluating the therapeutic effect of transarterial chemoembolization for hepatocellular carcinoma[J].World J Gastroenterol,2008,14(37):5738-5743.

[34]JIANG T,KAMBADAKONE A,KULKARNI NM,et al.Monitoring response to antiangiogenic treatment and predicting outcomes in advanced hepatocellular carcinoma using image biomarkers,CT perfusion,tumor density,and tumor size(RECIST)[J].Invest Radiol,2012,47(1):11-17.

[35]KOKABI N,LUDWIG JM,CAMACHO JC,et al.Baseline and early MR apparent diffusion coefficient quantification as a predictor of response of unresectable hepatocellular carcinoma to doxorubicin drug-eluting bead chemoembolization[J].J Vasc Interv Radiol,2015.[Epub ahead of print]

[36]VANDECAVEYE V,MICHIELSEN K,de KEYZER F,et al.Chemoembolization for hepatocellular carcinoma:1-month response determined with apparent diffusion coefficient is an independent predictor of outcome[J].Radiology,2014,270(3):747-757.

[37]SCHRAML C,SCHWENZER NF,MARTIROSIAN P,et al.Diffusion-weighted MRI of advanced hepatocellular carcinoma during sorafenib treatment:initial results[J].AJR Am J Roentgenol,2009,193(4):w301-w307.

[38]BRAREN R,ALTOMONTE J,SETTLES M,et al.Validation of preclinical multiparametric imaging for prediction of necrosis in hepatocellular carcinoma after embolization[J].J Hepatol,2011,55(5):1034-1040.

[39]TORIZUKA T,TAMAKI N,INOKUMA T,et al.Value of fluorine-18-FDG-PET to monitor hepatocellular carcinoma after interventional therapy[J].J Nucl Med,1994,35(12):1965-1969.

[40]HARTENBACH M,WEBER S,ALBERT NL,et al.Evaluating treatment response of radioembolization in intermediate-stage hepatocellular carcinoma patients using 18F-Fluoroethylcholine PET/CT[J].J Nucl Med,2015,56(11):1661-1666.

施引文献

资源附件(0)

访问统计